Severe Hypoglycemia In Diabetes Therapeutics
1. Zegalogue patent expiration
Treatment: Method of treating diabetic hypoglycemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Dosage: SOLUTION
More Information on Dosage
ZEGALOGUE family patents
